País: Canadá
Língua: inglês
Origem: Health Canada
DICLOFENAC SODIUM
SANDOZ CANADA INCORPORATED
S01BC03
DICLOFENAC
0.1%
SOLUTION
DICLOFENAC SODIUM 0.1%
OPHTHALMIC
5ML
Prescription
NONSTEROIDAL ANTI-INFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0114417004; AHFS:
APPROVED
2016-05-12
_Page 1 of 27_ _Sandoz Diclofenac Ophtha (Diclofenac Sodium)_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr SANDOZ DICLOFENAC OPHTHA Diclofenac Sodium Ophthalmic Solution Ophthalmic solution, 0.1% w/v for Topical use Anti-inflammatory agents, non-steroids Sandoz Canada Inc. 110, de Lauzon Street Boucherville, QC J4B 1E6 Canada Submission Control Number: 276264 Date of Initial Authorization: MAY 12, 2016 Date of Revision: JUL 13, 2023 _ _ _Sandoz Diclofenac Ophtha (Diclofenac Sodium) _ _Page 2 of 27_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and Male Potential 07/2023 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women 07/2023 SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ............................................................................................................. 4 1.1 Pediatrics ................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................ 4 4 DOSAGE AND ADMINISTRATION ................................................................................ 4 4.2 Recommended Dose and Dosage Adjustment ........................................................ 4 4.4 Administration ......................................................................................................... 5 4.5 Missed Dose .......................... Leia o documento completo